T he use of placebos as a research control has been the gold standard in randomized controlled trials since the mid-20th century. 1 By current standards, treatment is considered effective if proven to be superior to placebo. However, placebo response rates vary. 2 For example, conditions associated with patient-reported symptom severity without reliable physiologic correlates, such as chronic pain disorders, mental illnesses, and functional gastrointestinal disorders, are known to have high placebo response rates when compared with diseases measured with objective end points. 3, 4 Furthermore, it has been suggested that the magnitude of the placebo response might be increasing over time, [5] [6] [7] necessitating larger sample sizes to show efficacy of experimental therapies.
The high placebo response rate in irritable bowel syndrome (IBS) has garnered increasing attention over the years. 8 Estimates of the placebo response rate in IBS range between 15% and 72%, with pooled response rates of approximately 40%. [9] [10] [11] Several systematic reviews have attempted to identify predictors of placebo response in randomized controlled IBS drug trials, but have produced conflicting results. For example, although some reviews have found that more frequent study visits and longer study duration are associated with higher placebo response rates, 10 other studies 9, 11 have suggested that fewer visits and a shorter study duration predict a higher placebo response. In 2008, Kaptchuk et al 12 tested components of the placebo effect in IBS and concluded that the placebo response rate could be enhanced through contextual factors (eg, a warm patient-practitioner interaction compared with a neutral interaction).
We evaluated specific clinical predictors of the placebo response using original data from a placebocontrolled drug trial in IBS. A recent evaluation of 75 systematic reviews and meta-analyses performed in a range of medical specialties found that younger age was a predictor of placebo response in some medical specialties, but not in IBS, and that female sex was not associated with a higher placebo response rate in IBS or in the combined analysis of all conditions. 13 This same evaluation also noted that lower symptom severity at baseline, more recently performed studies, and study designs with a greater likelihood of receiving active treatment all were associated with higher placebo response rates in the combined analysis across medical conditions. 13 Not enough data were available for individual analysis of these variables in IBS specifically. Similarly, in a sample of 220 patients with functional dyspepsia who received placebo as part of a clinical trial, age and sex were not associated with placebo response. 14 The aim of the current study was to evaluate specific clinical predictors of the placebo response in a large sample of patients with IBS with constipation (IBS-C) receiving placebo as part of a 12-week, randomized, double-blind, phase III clinical trial. 15 
Methods

Study Sample
Patients receiving placebo as part of a phase III clinical trial with the experimental medication renzapride, a 5-hydroxytryptamine type-4 (5-HT 4 )-receptor agonist, and 5-HT 3 -receptor antagonist, were included in the current analysis. The larger trial was a multicenter study conducted at 201 secondary and tertiary care centers in 5 countries (United States, Argentina, Canada, Columbia, and Chile) in which women with IBS-C were randomized to renzapride 4 mg, 2 mg, or placebo for 12 weeks. Inclusion criteria included women ages 18 and older who met Rome II criteria for IBS-C and who reported at least moderate symptoms (defined as having at least mild symptoms on most [self-reported] of the baseline days) during the 2-week baseline period. Subjects were excluded if they reported recurrent diarrhea, a history of abdominal surgery, were pregnant/lactating, or had alarm features. Additional inclusion/exclusion criteria are described elsewhere. 15 
Responder Criteria
Abdominal pain placebo response. In accordance with Food and Drug Administration-recommended criteria, we used abdominal pain placebo response as our primary end point. 16 For the purpose of this study, abdominal pain placebo responders were classified using the criteria of 30% improvement from baseline in the average weekly abdominal pain scores for at least 6 of the 12 study weeks. Abdominal pain was measured daily using the following question: "On a scale of 1 to 10 (with 1 representing no pain and 10 representing the worst possible pain), how would you describe any abdominal pain/discomfort you experienced today?" Weekly abdominal pain scores were calculated for each participant using the average of 7 daily pain scores.
Adequate relief and complete spontaneous bowel movements. In secondary analyses, we evaluated responder status using adequate relief and complete spontaneous bowel movement (CSBM) definitions. Adequate relief of abdominal pain was measured as a dichotomous variable (yes/no) at the end of every study week. Patients were asked, "Have you experienced adequate relief of your abdominal pain/discomfort during the past week?" Patients who reported adequate relief for at least 6 of the 12 weeks of the treatment period were considered to be adequate relief placebo responders.
CSBMs were measured by first asking about daily spontaneous bowel movements (SBMs), defined as bowel movements occurring in the absence of laxative or enema use and then identifying how many of the SBMs were associated with a feeling of complete evacuation. A patient who reported an increase of 1 CSBMs per week compared with baseline for at least 6 of the 12 weeks of the treatment period was considered to be a CSBM placebo responder.
Demographics and Baseline Variables
Demographic variables included age, sex (all female), race, and duration of IBS in months. Other baseline variables included IBS-Quality of Life (QOL) 17 ; baseline variability in reported pain over 2 weeks (defined by the SD of the average daily pain scores during the 2-week baseline period); self-reported history of anxiety or depression; and concurrent medical illnesses (seasonal allergies, migraines, headaches, insomnia, dyspepsia, hypothyroidism, back pain, asthma, drug hypersensitivity, hypertension, myopia, anemia, and endometriosis). Additional information about methods and data collection, including a study flow-chart describing enrollment and allocation, has been provided in a previously published report, 15 a complete list of variables is included in Appendix 1.
Statistics
Data were stored and analyzed using STATA software version 14.2 (Stata, College Station, TX). Descriptive statistics were used to report mean pain scores, mean CSBMs, and responder frequency. Notably, there was a significant number of subjects with missing adequate relief data and thus our sample size for adequate relief analyses was smaller (n ¼ 443) than our sample size for the other variables (n ¼ 599). Even with a conservative sample size of 443, however, all analyses were adequately powered at 28 potential predictors.
Separate analyses were run to evaluate 3 dependent variables: (1) abdominal pain placebo response; (2) adequate relief placebo response; and (3) CSBM placebo response. For each dependent variable, we first ran univariate logistic regression models to evaluate unadjusted associations. Twenty-eight independent variables were entered into the regression model to evaluate predictors of the placebo response. These variables included age, QOL, baseline pain scores, baseline bowel movement frequency (CSBMs and SBMs), pain scores for weeks 1 to 3, mood scores, and medical comorbidities (Appendix 1). Next, we used backward elimination regression models with bootstrapping to reduce the number of independent variables. Bootstrapping is a nonparametric method of estimating statistical parameters by means of continued resampling of the empiric sample, and was used to increase the robustness of model results and decrease the chance of type 1 errors. The variables that remained significant in >50% of the 500 bootstrapped samples were kept and entered into a final multivariable logistic regression model.
Results
A total of 599 women with IBS-C were randomized to receive placebo as part of the phase III clinical trial. 15 Their mean age was 43.6 years (range, 18-65 y) and 79% were white. The median duration of IBS-C symptoms was 49 months.
Abdominal Pain Placebo Response
Overall, 29.0% of the women with IBS-C receiving placebo were abdominal pain placebo responders (ie, reported 30% improvement from baseline in the average weekly abdominal pain score for at least 6 of the 12 weeks of the treatment period). Between 15% and 25% of the women with IBS-C were weekly responders in any given week. Notably, 47% of the sample did not meet abdominal pain response criteria in any of the 12 study weeks, although all participants were included in the analyses. Figure 1 shows weekly trends in abdominal pain response to placebo.
Predictors of the abdominal pain placebo response. In univariate analysis, factors associated with an increased likelihood of abdominal pain placebo response included higher QOL scores, higher variability of baseline abdominal pain severity, higher maximum baseline pain severity, and reported abdominal pain relief in week 2 or in week 3. Higher final baseline pain severity (ie, the pain severity score recorded on the final day of baseline measurement) was associated with a decreased likelihood of abdominal pain placebo response (Table 1) .
In multivariate regression, factors that predicted an increased likelihood of abdominal pain placebo response included greater baseline variability of abdominal pain severity (odds ratio [OR], 1.71; P ¼ .016), higher maximum baseline pain severity (OR, 1.34; P < .001), and experiencing a placebo response in week 2 (OR, 2.23; P < .001) or week 3 (OR, 3.69; P < .001). Factors that predicted a decreased likelihood of abdominal pain placebo response were a greater number of baseline CSBMs (OR, 0.73; P ¼ .019) and higher final baseline pain severity (OR, 0.73; P < .001) ( Table 2 ).
Adequate Relief Placebo Response
A total of 43.6% of patients were adequate relief placebo responders (ie, patients reporting adequate relief for at least 6 weeks). Figure 1 shows weekly trends of participants reporting adequate relief over the course of the study. Between 30% and 45% of the women with IBS-C were weekly adequate relief placebo responders in any given week. A total of 21% of the sample did not meet adequate relief response criteria in any of the 12 study weeks.
Predictors of adequate relief placebo response. In univariate analysis, factors associated with an increased likelihood of adequate relief placebo response included more CSBMs at baseline and reported abdominal pain relief in weeks 2 or 3. Factors associated with decreased likelihood of adequate relief placebo response included higher final baseline pain rating, reported history of back pain, reported history of drug hypersensitivity, and higher number of reported medical comorbidities (Table 1) .
In multivariate regression, patients were significantly more likely to be adequate relief responders if they reported pain relief in week 2 (OR, 7.70), pain relief in week 3 (OR, 7.53), or higher CSBMs at baseline (OR, 1.70). A reported history of back pain was associated with a decreased likelihood of adequate relief placebo response (OR, 0.27) ( Table 2) .
Complete Spontaneous Bowel Movement Placebo Response
A total of 31.7% of the sample met CSBM placebo responder criteria (ie, patients reporting 1 additional CSBM compared with baseline for at least 6 weeks). Between 20% and 36% of the sample were weekly CSBM placebo responders in any given week. A total of 28.7% of the sample did not meet CSBM response criteria in any of the 12 study weeks. Figure 1 shows weekly trends of participants reporting CSBM relief over the course of the study. The mean weekly number of CSBMs significantly decreased from baseline to week 12 (baseline mean, 0.66; SD, 0.84; week 12 mean, 1.32; SD, 1.84; t(598), -9.19; P < .001).
Predictors of complete spontaneous bowel movement placebo response. In univariate analysis, factors associated with an increased likelihood of CSBM placebo response included reported abdominal pain relief in weeks 2 or 3 and a reported history of headaches. No factors were associated significantly with a decreased likelihood of CSBM placebo response (Table 1) . In multivariate regression, patients were significantly more likely to be CSBM placebo responders if they experienced early pain relief in week 2 (OR, 1.81), early pain relief in week 3 (OR, 3.11), or if they reported a history of headaches (OR, 1.84) ( Table 2) .
Discussion
This study reports specific clinical predictors of the placebo response in an IBS clinical trial. Our findings suggest that the strongest predictors of placebo response in women with IBS-C were early improvement of abdominal pain (ie, weeks 2 or 3), increased variability in baseline pain symptoms, and increased severity of baseline symptoms.
The most consistent predictor of placebo response in this study was early reported pain relief (in weeks 2 or 3). Although our primary outcome in this study was abdominal pain placebo response, early pain relief was the most consistent predictor for all of the responder definitions evaluated in this study including adequate relief placebo response and CSBM placebo response. This finding is consistent with the results of a recent study evaluating early response to eluxadoline in diarrhea-predominant IBS patients, which mentioned in passing that early response to treatment (placebo or drug) predicted sustained response to both placebo and drug. Specifically, 77.2% of patients taking placebo who responded within the first 4 weeks maintained the placebo response over 3 months and 66.3% of early responders maintained placebo response over 6 months (compared with 8.1% and 12.9% of patients who did not respond to placebo in the first 4 weeks). 18 This study reports baseline symptom variability or severity as predictors of the placebo response in a gastrointestinal population. Our findings regarding baseline pain variability as a predictor of abdominal pain placebo response is consistent with a recent analysis of 12 clinical trials in neuropathic pain that showed that increased variability in 7-day baseline pain diaries predicted response to placebo, but not to active medications. 19 Similarly, a trial evaluating pain variability in fibromyalgia in 2005 reported that greater baseline variability in pain predicted response to placebo but not to an active drug. 20 Although it is not yet clear why baseline variability in pain might differentially predict the pain placebo response, Farrar et al 19 suggested that this may be owing to the overlap between mind-body factors and physiologic pain-reduction pathways. Interestingly, baseline pain variability was only a predictor of our primary end point, abdominal pain placebo response, and was not a predictor of adequate relief response or of CSBM response, suggesting that this finding may be unique to symptoms of pain.
Similarly, our findings that baseline symptom severity predicted placebo response only applied to our primary outcome of abdominal pain. In our study, the abdominal pain placebo response was predicted by higher maximum baseline pain scores and fewer baseline CSBMs. The available literature regarding the association between baseline symptom severity and placebo response is mixed. A previous study evaluating predictors of placebo response in functional dyspepsia did not find any association between baseline symptom severity and response to placebo.
14 One analysis of 75 meta-analyses across 6 diverse disease groups (including 12 articles in gastroenterology) found that lower symptom severity at baseline predicted higher placebo response, 13 which is in contrast to the results of the current study. Interestingly, placebo research in autism 21 and depression [22] [23] [24] have suggested that lower baseline symptom burden may be associated with higher placebo response rates, while research in chronic neuropathic pain 25 and bipolar disorder 26 have found higher baseline pain scores to be associated with higher placebo response. Our findings may be influenced by the study design in which patients submitted daily symptom ratings for a 2-week, no-treatment baseline period before randomization, which may have provided more robust baseline data than typically is available in clinical trials. Furthermore, the inconsistent literature regarding baseline symptom severity as a predictor of placebo response may be better explained by our finding that baseline symptom variability was a significant predictor of placebo response. This possibility is supported by our finding that both higher maximum baseline pain as well as lower pain scores on the final day of the baseline period predicted abdominal pain placebo responders.
Other factors that were associated significantly with placebo response included higher QOL scores, which predicted increased likelihood of abdominal pain placebo response; self-reported history of back pain, which predicted decreased likelihood of adequate relief placebo response; and self-reported history of headache, which predicted increased likelihood of CSBM placebo response.
It is noteworthy that several factors were significant in the adequate relief univariate analyses that did not maintain significance in the multivariate analyses. Although the univariate analyses must be interpreted with caution because they do not account for correlations between individual predictors, our univariate analyses showed that patient-reported hypersensitivity to medications and higher number of medical comorbidities both were associated with a decreased likelihood to report adequate relief placebo response. These, combined with multivariate findings that history of back pain also was associated with a lower likelihood of adequate relief placebo response, might suggest that using adequate relief as a global end point may be influenced by centrally mediated mechanisms such as hypersensitivity or hypervigilance to pain and other physical symptoms. Based on our findings, it is possible that patients with more central sensitization could be less likely to meet adequate relief criteria in the placebo arm of an IBS study.
The results of this study have implications for clinical trial design in IBS. Based on our findings and other available research suggesting that baseline variability is a predictor of placebo response but not drug response, 19, 20 it is possible that removing patients with high pain variability during baseline monitoring or stratifying randomization by baseline pain variability could reduce the placebo effect while maintaining the drug effect. This may be especially relevant in light of recent research that has suggested that the magnitude of the placebo response is increasing over time, especially in conditions known to have high placebo response rates. [5] [6] [7] Of course, this requires further retrospective and even prospective replication and verification. Our findings regarding early response to placebo as a predictor of placebo response at the end of the study also may support the use of run-in periods to eliminate patients who respond early to placebo. However, early response to active medication also is associated with sustained response to treatment in IBS 18 and the only study in IBS to prospectively investigate the efficacy of a run-in period (testing acupuncture) did not find any differences when eliminating vs keeping run-in responders. 27 Caution is warranted concerning placebo run-in efficacy given that prospective and retrospective studies on the efficiency of the placebo run-in to detect drug-placebo differences have not been consistently successful. [28] [29] [30] It is possible that eliminating placebo responders during the run-in also would eliminate a significant number of medication responders.
Limitations of this study included its retrospective design, because our analyses were based on previously collected clinical trial data. 15 In this study, the abdominal pain placebo response rate (our primary end point) was approximately 29%, which is lower than the pooled response rate estimates for placebo in IBS of approximately 40%. Previously suggested explanations for the low abdominal pain placebo response rate in this study include a selected research population and lower frequency of study visits. 15 It is possible that our findings may have been different in a sample with a higher placebo response rate. Related to the previous point, the current study also was limited by the fact that it did not measure behavioral and psychobiological factors (eg, conditioning and expectancy) that are associated with the placebo response, 31, 32 and it did not measure contextual factors (eg, the therapeutic relationship and confidence in the treatment). 12, 33 These factors have been shown in multiple studies to be meaningful predictors of the placebo response. However, such behavioral, contextual, and psychobiological variables are not routinely collected in randomized controlled drug trials and, unfortunately, were not available as part of this data set.
Another limitation was regarding certain baseline demographic variables that were used in our models. For example, patient histories of medical and mental health comorbidities all were based on self-report and were not measured using validated questionnaires. Finally, the results of this study were limited only to women with IBS-C and we cannot generalize these findings to men or to subjects with other subtypes of IBS. The data evaluating sex differences in the placebo response were inconclusive. One recent systematic review found that men responded more strongly to placebo compared with women, 34 whereas another review reported no difference in placebo response between men and women.
